Once China and India were very important for increasing the stockpile of money to be used for trials. This may longer be the case. In November, Moffitt reports on their combo study with immunotherapies. All of big pharma, like lemmings, went down the very expensive path of anti-ctla4's, anti pd-1's and anti pdl-1's. What did they ALL find out? That the treatments are costly....$150,000 to $250,000 and that the ORR is very low so they went and combo'd with each other to raise it up...to some success...but not enough. They need a primer....there are only two....T-Vec and PV-10. T-Vec is toxic and PV-10 is not and works better. Inaddition they will all be sharing a small stage four market.
So.........Moffitt does a combo study with immunotherapies per possible request by big pharmas before initiating human combo trials. This has its roots in the fact that PV-10 successfully treated many Moffitt human patients that failed ALL available immunotherapies.
Which means....look for human combo trials with PV-10 funded by big pharma.
So what does that have to do with money for PVCT?
Eli Lily, Roche, Merck, Bristol Myers have got PVCT targeted and dialed in. Ely Lily and BMS both have tested PV-10 on mice themselves and know it to work.
My opinion.....with a raising....China and India become just a bonus. I think what I am seeing is that they are moving past that.
News 
Market Data 
Discover 
